Arcellx
Gaithersburg, US · Delaware corporation · 4,056 employees on LinkedIn · 9 known investors
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer. The company focuses on cell therapy for cancer treatment.
Founders & leadership
HL
Han LeeExecutive
RE
Rami ElghandourExecutive
Board
JC
Jill CarrollinBoard directorOperating Partner - Portfolio Value Creation at SR One Capital Management
AB
DY
TA
LT
Lewis T. Rusty WilliamsBoard director
DL
David LubnerBoard director
Investors · 9
LG Technology VenturesSanta Clara
New Enterprise Associates (NEA)Menlo Park · $200K – $40Mvia Kavita Patel · board
Quan CapitalShanghai
Samsara BioCapitalPalo Alto
Sixty Degree CapitalNorth York
Solasta VenturesBoston
SR One Capital ManagementRedwood City
NEA SecondaryreportedTimonium
Norwest Venture PartnersreportedMenlo Park · $10M – $30Mvia Tiba Aynechi · board
Reported raises · per SEC filings
Form D private placements$272.8M disclosed across 4 rounds · 2019–2023
▶$100MraisedFeb 2023 · 1 investors · BiotechnologyRule 506(b)
▶$100MraisedFeb 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Derek YoonDirector
- Michelle GilsonExecutive Officer
- Rami ElghandourExecutive Officer, Director
- Ali BehbahaniDirector
- Olivia WareDirector
- David LubnerDirector
- Kavita PatelDirector
- Christopher HeeryExecutive Officer
- Jill CarrollDirector
- Offering amount
- $100M
- Amount sold
- $100M
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedMar 2022 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedMar 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Derek YoonDirector
- David LubnerDirector
- Lance ThibaultExecutive Officer
- Ali BehbahaniDirector
- Jill CarrollDirector
- Rami ElghandourExecutive Officer, Director
- Kavita PatelDirector
- Lewis T. WilliamsDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$120MraisedJul 2021 · 32 investors · BiotechnologyRule 506(b)
▶$120MraisedJul 2021 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Han LeeExecutive Officer
- Lewis T. Rusty WilliamsDirector
- Jill CarrollDirector
- David LubnerDirector
- Ali BehbahaniDirector
- Derek YoonDirector
- Rami ElghandourExecutive Officer, Director
- Tiba AynechiDirector
- Offering amount
- $120M
- Amount sold
- $120M
- Finders' fees
- $570K
- Placement agents
- Solebury Capital LLC
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$42.8MraisedOct 2019 · 18 investors · BiotechnologyRule 506(b)
▶$42.8MraisedOct 2019 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ali BehbahaniDirector
- Hugo BeekmanDirector
- David HilbertExecutive Officer, Director
- Han LeeExecutive Officer
- Lewis T. Rusty WilliamsDirector
- Tiba AynechiDirector
- Jill CarrollDirector
- Roger SawhneyDirector
- Offering amount
- $83.7M
- Amount sold
- $42.8M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapKite Pharma8 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Exelixis6 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Companies competing with Arcellx for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
So, You Want to Join a Life Science Startup? A 2026 Resource Guide for Job Seekers | BioBuzzbiobuzz.io · Aug 2026Frequently asked questions
- What does Arcellx do?
- Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer. The company focuses on cell therapy for cancer treatment.
- Who are Arcellx's investors?
- Arcellx's investors include LG Technology Ventures, New Enterprise Associates (NEA), Quan Capital, Samsara BioCapital, Sixty Degree Capital, Solasta Ventures, SR One Capital Management, NEA Secondary and 1 more.
- How much funding has Arcellx raised?
- Arcellx has disclosed $272.8M raised across 4 rounds.
- Where is Arcellx headquartered?
- Arcellx is headquartered in Gaithersburg, US.